ClinicalTrials.gg
RecruitingNCT07375758Updated Apr 13, 2026

A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.

A Phase 1/2 interventional study of MIL116 and Matching Placebo in Immunoglobulin A Nephropathy, sponsored by Beijing Mabworks Biotech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Beijing Mabworks Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Glomerulonephritis, IGA with a site in China — 57 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
37th of 109
130 · median 84
Started
2026
with 24 others
Phase 1/2
2 of 127
2 open now
Primary completion
2028-06
later than 48 of 72 live
Registered
101st of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 37th largest by planned enrollment of the 109 interventional ones that give a count, is one of 25 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 48 of the 72 other live ones, and was the 101st registered.

Glomerulonephritis, IGA

277 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

57 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 57 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Glomerulonephritis, IGA studies recruiting now, 40 (58%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.

03

Conditions studied

  • Immunoglobulin A Nephropathy

Keywords

  • Anti-APRIL monoclonal antibody
  • MIL116
  • IgAN
  • CLYM116
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Phase Ia:

  1. Able to understand and voluntarily sign the written Form (ICF), willing and able to comply with all study requirements;
  2. Healthy participants aged 18 to 55 years (inclusive) at the time of signing the ICF, of either sex;
  3. Have a (BMI) between 19 to 32 kg/m² (inclusive) and a body weight ≥ 50 kg at screening;
  4. Assessed to be in good health status based on medical history, physical examination, vital signs, 12-lead (ECG), and clinical laboratory tests, with no abnormalities;
  5. Have a total immunoglobulin G (IgG) level > 10 g/L at screening; and immunoglobulin A (IgA) and immunoglobulin M (IgM) levels within the normal reference ranges.

Phase Ib\&II:

  1. Able to understand and voluntarily sign the written ICF, and willing and able to comply with all study requirements;
  2. Aged ≥ 18 years at the time of signing the ICF, of either sex, with a BMI ≥ 16 kg/m²;
  3. -confirmed diagnosis of IgA Nephropathy (IgAN). Participants must have a 24-hour urine protein-to-creatinine ratio (UPCR) ≥ 0.5 g/g or 24-hour urine protein ≥ 0.75 g prior to the first dose;
  4. Have been receiving an optimized and stable dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor antagonist (ARB). If currently receiving sodium-glucose cotransporter 2 inhibitors (SGLT2i) and / or endothelin receptor antagonists (ERA), the same administration and dose stability requirements apply for;
  5. Have acceptable hematologic, hepatic, coagulation, and renal function as assessed by clinical laboratory tests.

Exclusion criteria

Exclusion Criteria:

-

Phase Ia:

  1. Nursing, lactating or pregnant, or who have plans to become pregnant during the study
  2. History or evidence of any disease, disorder, or condition that, in the investigator's judgment, may pose a risk to the participants' safety, interfere with the study assessments, or render the subject unsuitable for participation, including but not limited to respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurologic, cardiovascular, psychiatric, or other systemic diseases;
  3. Any confirmed or suspected or immunodeficiency condition, including (HIV) infection or asplenia; history of recurrent or severe infections, or long-term use of immunosuppressive agents within 6 months prior to screening;
  4. History of chronic infection (e.g., tuberculosis, osteomyelitis) or any infectious disease requiring hospitalization or treatment with antiviral, antibiotic, or antifungal agents within 28 days prior to administration of the study drug;
  5. Use of any prescription medications, over-the-counter (OTC) drugs, herbal products, topical products, or dietary supplements within 28 days prior to administration of the study drug or for within 5 half-lives of the drug (whichever is longer);
  6. Participation in any clinical study of an drug or medical device, or receipt of any investigational study drug, within 3 months prior to administration of the study drug or within 5 half-lives (whichever is longer);
  7. Receipt of any marketed or investigational antibody or biologic therapy (including immunoglobulin products, monoclonal antibodies, or antibody fragments) within 28 days prior to administration of the study drug or within 5 half-lives (whichever is longer);
  8. History of drug abuse or substance dependence, or a positive urine drug abuse screening result during the screening period.

Phase Ib\&II:

  1. Secondary IgAN or IgA vasculitis (Henoch-Schönlein purpura), as diagnosed by the investigator;
  2. Presence of chronic kidney disease of causes other than IgAN;
  3. Other significant pathological abnormalities identified on kidney ;
  4. Kidney biopsy demonstrating tubular-interstitial fibrosis > 50% or glomerular crescents involving > 25% of glomeruli. Note: The most recent kidney biopsy will be prioritized for eligibility assessment;
  5. Clinical suspicion of rapidly progressive glomerulonephritis based on an estimated (eGFR) decline ≥ 50% within 3 months prior to the screening visit;
  6. Nephrotic syndrome, defined as 24-hour urine protein > 3.5 g accompanied by hypoalbuminemia (serum albumin \< 30 g/L). Subjects with isolated nephrotic-range proteinuria (> 3.5 g/d) are excluded;
  7. Receipt of rituximab or any B-cell depleting agent within 6 months prior to screening. Participants with \< 200 cells/μL are excluded;
  8. Total IgG level \< 6 g/L at screening; uncontrolled type 2 diabetes mellitus, defined as (HbA1c) > 8%; or diagnosis of type 1 diabetes mellitus;
  9. History of prior treatment with any APRIL-targeted medication;
  10. Receipt of biologic agents, such as belimumab or eculizumab, within 3 months prior to the first dose of the study drug;
  11. Receipt of cyclophosphamide within 3 months prior to the first dose; use of other immunosuppressive agents within 28 days prior to the first dose, including but not limited to azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine, methotrexate, or tripterygium wilfordii; systemic used at an average daily dose equivalent to ≥40 mg prednisone for more than 14 days within 28 days prior to the screening visit, or use of oral delayed-release budesonide capsules within 1 year prior to the screening visit.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    MIL116

    Drug: MIL116

  • Placebo comparator
    Placebo

    Drug: Matching Placebo

Interventions

  • DrugMIL116

    MIL116 is supplied as sterile solution for subcutaneous (SC) injection.

  • DrugMatching Placebo

    Placebo is to be administered at a matching volume by SC injection.

06

What researchers measure

Primary outcomes

  1. Phase Ia: Safety and Tolerability of Single Ascending Doses of MIL116 in Healthy Participants.

    Percentage of Participants with AEs and SAEs assessed by NCI CTCAE v5.0.

    Time frame: up to 6 months after enrollment

  2. Phase Ib: Safety and Tolerability of Multiple-Ascending Doses of MIL116 in IgAN Participants.

    Description: Percentage of Participants with AEs and SAEs assessed by NCI CTCAE v5.0.

    Time frame: up to 18 months after enrollment

  3. Phase II: Change in Gd-IgA1 from Baseline at Week 12

    Evaluate the degree and percentage change of Gd-IgA1 from baseline.

    Time frame: up to 18 months after enrollment

  4. Change in 24-Hour Urine UPCR from Baseline at Week 24

    Evaluate the degree and percentage change of 24-hour urine UPCR from baseline

    Time frame: up to 18 months after enrollment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jun 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 29, 2026
StartActual
Feb 5, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07375758
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Feb 5, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Apr 13, 2026

Study contacts

Hong Zhang, Doctor
Contact
hongzh@bjmu.edu.cn
(+86)010-83572388

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion